Pharma ingredient maker Sequent Scientific today said it will invest Rs 150 crore in expansion plans, which include foraying into new therapeutic segment and setting up of greenfield facilities.
The company in a statement said that it will invest Rs 150 crore in the next two years in expanding its presence to three new therapeutic areas.
It, however, did not provide the details regarding the sourcing of the investments.
"Expansion into new therapeutic segments will not only enable the company's presence in high growth high margin segment but would also strengthen its product portfolio," Sequent Chairman and Managing Director K R Ravishankar said.
The company said it has signed a memorandum of understanding (MoU) with the Karnataka government for setting up three manufacturing facilities in Bangalore.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app